Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Aligning, Appraising, and Simplifying Scientific Data Strengthens Promotional Claims

Pharmaceutical companies must convert complex scientific data into clear promotional materials that comply with regulatory standards and effectively communicate with healthcare professionals and patients. This involves evaluating data alignment, assessing evidence quality, and simplifying messaging. Missteps can result in legal and financial repercussions.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Vodori on MarketScale.

By Annalise Ludtke ·
Share
Aligning, Appraising, and Simplifying Scientific Data Strengthens Promotional Claims

Key takeaways

01

Evaluate new scientific data for alignment with drug's indication and regulatory constraints.

02

Thorough appraisal of evidence quality is crucial for credible claims.

03

Clear communication requires simplifying complex data while maintaining accuracy.

The pharmaceutical industry faces the challenge of converting complex medical and scientific information into clear, effective promotional claims. This process is critical as it balances the need for accurate scientific communication with the requirement for impactful marketing. The stakes are high, as promotional materials must adhere to stringent regulatory standards while also appealing to healthcare professionals and patients. Missteps can lead to significant legal and financial repercussions, making it essential for pharmaceutical companies to get this process right.

Missteps can lead to significant legal and financial repercussions, making it essential for pharmaceutical companies to get this process right.

How do teams navigate the complexities of transforming dense scientific data into clear, approvable promotional material without losing accuracy or impact?

On this episode of Amend & Progress, hosted by Annalise Ludtke, Joe DiCapite, Director of Strategy for the UK and Europe at Vodori, delves into the intricate process of converting medical and scientific information into claims. Together, they discuss the challenges, best practices, and the importance of inter-team collaboration in ensuring successful outcomes.

Key Discussion Points

  • Ensure appropriateness: Teams must first evaluate whether new scientific data aligns with their drug's indication and regulatory constraints to determine its suitability for promotional claims.
  • Assess evidence quality: A thorough appraisal of the evidence's quality, including study design and statistical significance, is crucial to ensure the claim's credibility and withstand scrutiny from competitors and regulators.
  • Effective communication: Transforming complex scientific data into clear, impactful, and accurate claims requires simplifying jargon while maintaining precision, tailored to different audience needs, and considering the overall impression of the promotional material.

Joe DiCapite brings extensive experience in medical writing, medical affairs, and marketing. His background includes a strong foundation in the pharmaceutical industry, with a focus on critical appraisal and compliance processes. His expertise spans both the strategic and operational aspects of converting scientific data into promotional claims, making him a valuable voice in this field.

Vodori

Part of this channel

Vodori

Faster market access through compliant life science content review.

Visit the channel

About the author

AL
Annalise Ludtke

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

NIH is harmonizing 12 petabytes of biomedical data to power the next wave of health AI

NIH is harmonizing 12 petabytes of biomedical data to power the next wave of health AI

The NIH is undertaking a cross-agency initiative to standardize 70 years of biomedical data, totaling 12 petabytes, to enhance health AI capabilities. This effort aims to establish a robust foundation for enterprise health IT leaders to deploy AI technologies effectively. By harmonizing this vast amount of data, the NIH is paving the way for significant advancements in health AI research and applications.

  • 01The NIH is standardizing 12 petabytes of biomedical data to advance health AI.
  • 02This initiative aims to create a robust foundation for AI deployment in healthcare.
  • 03Harmonizing historical biomedical data is critical for future health AI research.

Jul 24, 2026

ONC marks universal EHR adoption and one billion TEFCA health records exchanged in inaugural Coordinator's Quarterly

ONC marks universal EHR adoption and one billion TEFCA health records exchanged in inaugural Coordinator's Quarterly

The Office of the National Coordinator for Health Information Technology (ONC) has announced universal adoption of Electronic Health Records (EHR) across U.S. healthcare. Additionally, the Trusted Exchange Framework and Common Agreement (TEFCA) has facilitated the exchange of one billion health records. These milestones emphasize the significant progress in digital health record interoperability in the United States.

  • 01Universal adoption of Electronic Health Records (EHR) has been achieved across the U.S. healthcare system.
  • 02TEFCA has successfully facilitated the exchange of one billion health records.
  • 03These developments mark significant progress in the interoperability of digital health records.

Jul 23, 2026

OpenEvidence expands clinical AI across NewYork-Presbyterian, Columbia, and Weill Cornell as Linux Foundation targets open-source health stack

OpenEvidence expands clinical AI across NewYork-Presbyterian, Columbia, and Weill Cornell as Linux Foundation targets open-source health stack

OpenEvidence is expanding its clinical AI technologies across major New York healthcare institutions including NewYork-Presbyterian, Columbia, and Weill Cornell. Concurrently, the Linux Foundation is establishing efforts to create an open-source health technology stack. Delaware is expanding its Health Information Exchange (HIE) access.

  • 01OpenEvidence expands clinical AI deployment in prominent New York-based healthcare facilities.
  • 02The Linux Foundation is developing an open-source stack for healthcare technology.
  • 03Delaware is enhancing access to its Health Information Exchange (HIE).

Jul 22, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

JD
Joe DiCapite

Director of Strategy for the UK and Europe

Vodori

Joe DiCapite brings extensive experience in medical writing, medical affairs, and marketing. His background includes a strong foundation in the pharmaceutical industry, with a focus on critical appraisal and compliance processes. His expertise spans both the strategic and operational aspects of converting scientific data into promotional claims.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512